Black Diamond Therapeutics
MA - CambridgeBiotechnology
Focus: Black Diamond Therapeutics is an oncology-focused biotech company specializing in allosteric mutant oncogene inhibitors, operating from Cambridge, MA with a public listing on NASDAQ (BDTX).
Profile data last refreshed 1h ago · AI intelligence enriched 2w ago
Open Jobs
0
About Black Diamond Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow Black Diamond Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Early-stage
4 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Azathioprine 50Mg Tab
Therapeutic EquivalencyClinical Trials (1)
NCT03930264Bioequivalence of Azathioprine Suspension 10 mg/mL (Jayempi) Versus Azathioprine Tablet 50mg (Imurek®)
Phase 1Help build intelligence for Black Diamond Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.